Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kennedy Tobin"'
Autor:
Kathleen Kennedy Tobin
Publikováno v:
The Eugene O'Neill Review. 42:206-209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c02d763781111a1b0336eb954bf2c56
https://doi.org/10.5325/eugeoneirevi.42.2.0206
https://doi.org/10.5325/eugeoneirevi.42.2.0206
Autor:
Hidehiro Yamane, Geoffrey M. Lynn, Charles-Antoine Dutertre, John P. Finnigan, Nina Bhardwaj, Matthew P. Mulé, John S. Tsang, Glennys V. Reynoso, Vincent L. Coble, Jessica A. Hamerman, Xiao Meng Zhang, Kennedy Tobin, Andrew S. Ishizuka, Faezzah Baharom, Ramiro A. Ramirez-Valdez, Florent Ginhoux, Robert A. Seder, Heather D. Hickman, Ahad Khalilnezhad, Andrew J. Martins
Publikováno v:
Nature immunology
Personalized cancer vaccines are a promising approach for inducing T cell immunity to tumor neoantigens. Using a self-assembling nanoparticle vaccine that links neoantigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a), we show how the route
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fcfbea9dd3f09b85a4cef16cce85b0e
http://europepmc.org/articles/PMC7746638
http://europepmc.org/articles/PMC7746638
Autor:
Richard Laga, Robert A. Seder, Hidehiro Yamane, Nicolas J. Blobel, Yaakov Itzkowitz, Eliane Piaggio, Faezzah Baharom, Vincent L. Coble, Leonard W. Seymour, Brennan Decker, Olivier Lantz, Christine Sedlik, Ramiro A. Ramirez-Valdez, Justin Cheung, Joseph R. Francica, Geoffrey M. Lynn, Neeha Zaidi, Yaling Zhu, Sarah R. Nichols, Joshua D. Bernstock, Mateusz Maciejewski, Andrew S. Ishizuka, Joshua M. Gammon, Jordan Denizeau, Brian Francica, Christopher M. Jewell, Philippe De La Rochere, Charles G. Drake, Kennedy Tobin, Margery G. Smelkinson
Publikováno v:
Nature Biotechnology
Nature Biotechnology, Nature Publishing Group, 2020, ⟨10.1038/s41587-019-0390-x⟩
Nature biotechnology
Nature Biotechnology, 2020, ⟨10.1038/s41587-019-0390-x⟩
Nature Biotechnology, Nature Publishing Group, 2020, Epub ahead of print. ⟨10.1038/s41587-019-0390-x⟩
Nature Biotechnology, 2020, Epub ahead of print. ⟨10.1038/s41587-019-0390-x⟩
Nature Biotechnology, Nature Publishing Group, 2020, ⟨10.1038/s41587-019-0390-x⟩
Nature biotechnology
Nature Biotechnology, 2020, ⟨10.1038/s41587-019-0390-x⟩
Nature Biotechnology, Nature Publishing Group, 2020, Epub ahead of print. ⟨10.1038/s41587-019-0390-x⟩
Nature Biotechnology, 2020, Epub ahead of print. ⟨10.1038/s41587-019-0390-x⟩
International audience; Personalized cancer vaccines targeting patient-specific neoantigens are a promising cancer treatment modality; however, neoantigen physicochemical variability can present challenges to manufacturing personalized cancer vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::644c10d50fa2842221d97056616010fc
https://www.hal.inserm.fr/inserm-02479477/document
https://www.hal.inserm.fr/inserm-02479477/document
Autor:
Andrew S. Ishizuka, Brennan Decker, Faezzah Baharom, Geoffrey M. Lynn, Vincent L. Coble, Hide Yamane, Andrei Ramirez-Valdez, Kennedy Tobin, Robert A. Seder, Yaling Zhu
Publikováno v:
Cancer Immunology Research. 7:IA29-IA29
T cells recognizing tumor-specific neoantigens can mediate effective anti-tumor immunity and provide the rationale for personalized cancer vaccines (PCVs). Current approaches for PCVs include synthetic long peptides given with adjuvants or RNA vaccin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7dc9d6aa1b0a355ab285e021ed90e8c
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-ia29
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-ia29